Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

NCT ID: NCT01201356

Last Updated: 2021-04-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

4125 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-13

Study Completion Date

2018-10-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to collect long-term safety and tolerability, long-term efficacy, and health outcome data in all patients currently ongoing in the fingolimod multiple sclerosis clinical development program. This study combined all currently ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned studies into one single long-term extension protocol that provided patients with continuous treatment until fingolimod was registered, commercially available, and reimbursed in the respective countries.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study had two parts:

* Part 1, collecting long-term safety, tolerability, efficacy and health outcomes data through approximately 30-Jun-2016 until all end of study (EOS) visits of Part 1 and last follow-up visit through Jan-2017 and
* Part 2, collecting limited safety and tolerability data until approximately 30 Jun 2018, in a subset of patients who participated in Part 1, and other eligible patients from ongoing fingolimod trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsing Forms of Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fingolimod 0.5 mg/day

Open-label fingolimod 0.5 mg, taken orally once daily

Group Type EXPERIMENTAL

Fingolimod

Intervention Type DRUG

0.5 mg/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fingolimod

0.5 mg/day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FTY720

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Patients who have completed selected ongoing or planned trials with FTY720.

Exclusion Criteria

* Premature permanent discontinuation of a previous fingolimod study.
* Pregnant or nursing (lactating) women.
* Women of child-bearing potential, UNLESS they are using two birth control methods, at least 1 of which must be hormonal contraception, tubal sterilization, partner's vasectomy or intrauterine device.
* Chronic disease of the immune system, other than multiple sclerosis, which may require immunosuppressive treatment.
* Diabetic patients with moderate or severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy and uncontrolled diabetic patients with HbA1c \> 8%.
* Active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or have positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests.
* Previous treatment with cladribine, cyclophosphamide or mitoxantrone.
* Treatment with immunoglobulins and/or monoclonal antibodies (including Natalizumab) in the past 3 months during the previous fingolimod study:
* Any of the following cardiovascular conditions that have developed during the previous fingolimod study:

* Myocardial infarction within the past 6 months prior to entry in the extension study or with current unstable ischemic heart disease;
* Cardiac failure (Class III, according to New York Heart Association Classification) or any severe cardiac disease as determined by the investigator;
* Arrhythmia requiring current treatment with Class III antiarrhythmic drugs (e.g., amiodarone, bretylium, sotalol, ibutilide, azimilide, dofetilide)
* History or presence of a third degree AV block
* Proven history of sick sinus syndrome or sino-atrial heart block
* Known history of angina pectoris due to coronary spasm or Raynaud's phenomenon
* Any of the following pulmonary conditions during the previous fingolimod study:

* Severe respiratory disease or pulmonary fibrosis diagnosed (during the previous fingolimod study)
* Active tuberculosis
* Alcohol abuse, chronic liver disease during the previous fingolimod study.

The patient must have participated in a previous fingolimod trial to be eligible to participate in this trial.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novartis Investigative Site

Cona, FE, Italy

Site Status

Novartis Investigative Site

Foggia, FG, Italy

Site Status

Novartis Investigative Site

Florence, FI, Italy

Site Status

Novartis Investigative Site

Genova, GE, Italy

Site Status

Novartis Investigative Site

Pozzilli, IS, Italy

Site Status

Novartis Investigative Site

Rome, Lazio, Italy

Site Status

Novartis Investigative Site

Milan, MI, Italy

Site Status

Novartis Investigative Site

Milan, MI, Italy

Site Status

Novartis Investigative Site

Palermo, PA, Italy

Site Status

Novartis Investigative Site

Fidenza, PR, Italy

Site Status

Novartis Investigative Site

Pavia, PV, Italy

Site Status

Novartis Investigative Site

Ravenna, RA, Italy

Site Status

Novartis Investigative Site

Roma, RM, Italy

Site Status

Novartis Investigative Site

Roma, RM, Italy

Site Status

Novartis Investigative Site

Roma, RM, Italy

Site Status

Novartis Investigative Site

Roma, RM, Italy

Site Status

Novartis Investigative Site

Siena, SI, Italy

Site Status

Novartis Investigative Site

Orbassano, TO, Italy

Site Status

Novartis Investigative Site

Udine, UD, Italy

Site Status

Novartis Investigative Site

Gallarate, VA, Italy

Site Status

Novartis Investigative Site

Vicenza, VI, Italy

Site Status

Novartis Investigative Site

Verona, VR, Italy

Site Status

Novartis Investigative Site

Viterbo, VT, Italy

Site Status

Novartis Investigative Site

Napoli, , Italy

Site Status

Novartis Investigative Site

Napoli, , Italy

Site Status

Novartis Investigative Site

Napoli, , Italy

Site Status

Novartis Investigative Site

Irbid, , Jordan

Site Status

Novartis Investigative Site

Kuala Lumpur, Kuala Lumpur, Malaysia

Site Status

Novartis Investigative Site

Kuala Lumpur, , Malaysia

Site Status

Novartis Investigative Site

Breda, CK, Netherlands

Site Status

Novartis Investigative Site

Amsterdam, , Netherlands

Site Status

Novartis Investigative Site

Amsterdam, , Netherlands

Site Status

Novartis Investigative Site

Blaricum, , Netherlands

Site Status

Novartis Investigative Site

Enschede, , Netherlands

Site Status

Novartis Investigative Site

Gouda, , Netherlands

Site Status

Novartis Investigative Site

Nieuwegein, , Netherlands

Site Status

Novartis Investigative Site

Nijmegen, , Netherlands

Site Status

Novartis Investigative Site

Rotterdam, , Netherlands

Site Status

Novartis Investigative Site

Sittard-Geleen, , Netherlands

Site Status

Novartis Investigative Site

Tilburg, , Netherlands

Site Status

Novartis Investigative Site

Lillehammer, , Norway

Site Status

Novartis Investigative Site

Molde, , Norway

Site Status

Novartis Investigative Site

Stavanger, , Norway

Site Status

Novartis Investigative Site

Panama City, , Panama

Site Status

Novartis Investigative Site

Panama City, , Panama

Site Status

Novartis Investigative Site

Jesus Maria, Lima region, Peru

Site Status

Novartis Investigative Site

San Isidro, Lima region, Peru

Site Status

Novartis Investigative Site

La Perla, Provincia Constitucional del Callao, Peru

Site Status

Novartis Investigative Site

Bialystok, , Poland

Site Status

Novartis Investigative Site

Bialystok, , Poland

Site Status

Novartis Investigative Site

Bydgoszcz, , Poland

Site Status

Novartis Investigative Site

Gdansk, , Poland

Site Status

Novartis Investigative Site

Katowice, , Poland

Site Status

Novartis Investigative Site

Katowice, , Poland

Site Status

Novartis Investigative Site

Lodz, , Poland

Site Status

Novartis Investigative Site

Poznan, , Poland

Site Status

Novartis Investigative Site

Warsaw, , Poland

Site Status

Novartis Investigative Site

Warsaw, , Poland

Site Status

Novartis Investigative Site

Warsaw, , Poland

Site Status

Novartis Investigative Site

Warsaw, , Poland

Site Status

Novartis Investigative Site

Amadora, , Portugal

Site Status

Novartis Investigative Site

Coimbra, , Portugal

Site Status

Novartis Investigative Site

Lisbon, , Portugal

Site Status

Novartis Investigative Site

Porto, , Portugal

Site Status

Novartis Investigative Site

Porto, , Portugal

Site Status

Novartis Investigative Site

Setúbal, , Portugal

Site Status

Novartis Investigative Site

Bucharest, , Romania

Site Status

Novartis Investigative Site

Bucharest, , Romania

Site Status

Novartis Investigative Site

Bucharest, , Romania

Site Status

Novartis Investigative Site

Craiova, , Romania

Site Status

Novartis Investigative Site

Târgu Mureş, , Romania

Site Status

Novartis Investigative Site

Samara, Samara Oblast, Russia

Site Status

Novartis Investigative Site

Kazan', , Russia

Site Status

Novartis Investigative Site

Kazan', , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Nizhny Novgorod, , Russia

Site Status

Novartis Investigative Site

Nizhny Novgorod, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Smolensk, , Russia

Site Status

Novartis Investigative Site

Yekaterinburg, , Russia

Site Status

Novartis Investigative Site

Bratislava, Slovak Republic, Slovakia

Site Status

Novartis Investigative Site

Bratislava, , Slovakia

Site Status

Novartis Investigative Site

Bratislava, , Slovakia

Site Status

Novartis Investigative Site

Martin, , Slovakia

Site Status

Novartis Investigative Site

Trnava, , Slovakia

Site Status

Novartis Investigative Site

Cape Town, , South Africa

Site Status

Novartis Investigative Site

Durban, , South Africa

Site Status

Novartis Investigative Site

Rosebank, , South Africa

Site Status

Novartis Investigative Site

Gyeonggi-do, Korea, South Korea

Site Status

Novartis Investigative Site

Seoul, , South Korea

Site Status

Novartis Investigative Site

Seoul, , South Korea

Site Status

Novartis Investigative Site

Málaga, Andalusia, Spain

Site Status

Novartis Investigative Site

Seville, Andalusia, Spain

Site Status

Novartis Investigative Site

Bilbao, Basque Country, Spain

Site Status

Novartis Investigative Site

Donostia / San Sebastian, Basque Country, Spain

Site Status

Novartis Investigative Site

Barcelona, Catalonia, Spain

Site Status

Novartis Investigative Site

Barcelona, Catalonia, Spain

Site Status

Novartis Investigative Site

L'Hospitalet de Llobregat, Catalonia, Spain

Site Status

Novartis Investigative Site

Santiago de Compostela, Galicia, Spain

Site Status

Novartis Investigative Site

Valencia, Valencia, Spain

Site Status

Novartis Investigative Site

Valencia, Valencia, Spain

Site Status

Novartis Investigative Site

Barcelona, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Santa Cruz de Tenerife, , Spain

Site Status

Novartis Investigative Site

Gothenburg, , Sweden

Site Status

Novartis Investigative Site

Linköping, , Sweden

Site Status

Novartis Investigative Site

Stockholm, , Sweden

Site Status

Novartis Investigative Site

Stockholm, , Sweden

Site Status

Novartis Investigative Site

Umeå, , Sweden

Site Status

Novartis Investigative Site

Aarau, , Switzerland

Site Status

Novartis Investigative Site

Basel, , Switzerland

Site Status

Novartis Investigative Site

Carouge, , Switzerland

Site Status

Novartis Investigative Site

Lausanne, , Switzerland

Site Status

Novartis Investigative Site

Lugano, , Switzerland

Site Status

Novartis Investigative Site

Sankt Gallen, , Switzerland

Site Status

Novartis Investigative Site

Zurich, , Switzerland

Site Status

Novartis Investigative Site

Istanbul, TUR, Turkey (Türkiye)

Site Status

Novartis Investigative Site

Ankara, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Ankara, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Antalya, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Gaziantep, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Haseki / Istanbul, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Istanbul, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Istanbul, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Istanbul, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Izmir, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Izmir, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Mersin, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Samsun, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Trabzon, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Yenisehir / Izmir, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Truro, Cornwall, United Kingdom

Site Status

Novartis Investigative Site

Brighton, East Sussex, United Kingdom

Site Status

Novartis Investigative Site

Salford, Manchester, United Kingdom

Site Status

Novartis Investigative Site

Headington, Oxfordshire, United Kingdom

Site Status

Novartis Investigative Site

Sheffield, South Yorkshire, United Kingdom

Site Status

Novartis Investigative Site

Stoke-on-Trent, Staffordshire, United Kingdom

Site Status

Novartis Investigative Site

Birmingham, , United Kingdom

Site Status

Novartis Investigative Site

Bristol, , United Kingdom

Site Status

Novartis Investigative Site

Dundee, , United Kingdom

Site Status

Novartis Investigative Site

Edinburgh, , United Kingdom

Site Status

Novartis Investigative Site

Essex, , United Kingdom

Site Status

Novartis Investigative Site

Cullman, Alabama, United States

Site Status

Novartis Investigative Site

Oceanside, California, United States

Site Status

Novartis Investigative Site

Sacramento, California, United States

Site Status

Novartis Investigative Site

San Francisco, California, United States

Site Status

Novartis Investigative Site

Washington D.C., District of Columbia, United States

Site Status

Novartis Investigative Site

Jacksonville, Florida, United States

Site Status

Novartis Investigative Site

Maitland, Florida, United States

Site Status

Novartis Investigative Site

Miami, Florida, United States

Site Status

Novartis Investigative Site

Sunrise, Florida, United States

Site Status

Novartis Investigative Site

Tallahassee, Florida, United States

Site Status

Novartis Investigative Site

Tampa, Florida, United States

Site Status

Novartis Investigative Site

Vero Beach, Florida, United States

Site Status

Novartis Investigative Site

Atlanta, Georgia, United States

Site Status

Novartis Investigative Site

Kansas City, Kansas, United States

Site Status

Novartis Investigative Site

Lenexa, Kansas, United States

Site Status

Novartis Investigative Site

Baltimore, Maryland, United States

Site Status

Novartis Investigative Site

Baltimore, Maryland, United States

Site Status

Novartis Investigative Site

Kansas City, Missouri, United States

Site Status

Novartis Investigative Site

Lebanon, New Hampshire, United States

Site Status

Novartis Investigative Site

Albuquerque, New Mexico, United States

Site Status

Novartis Investigative Site

New York, New York, United States

Site Status

Novartis Investigative Site

Durham, North Carolina, United States

Site Status

Novartis Investigative Site

Raleigh, North Carolina, United States

Site Status

Novartis Investigative Site

Toledo, Ohio, United States

Site Status

Novartis Investigative Site

Oklahoma City, Oklahoma, United States

Site Status

Novartis Investigative Site

Tulsa, Oklahoma, United States

Site Status

Novartis Investigative Site

Tualatin, Oregon, United States

Site Status

Novartis Investigative Site

Pittsburgh, Pennsylvania, United States

Site Status

Novartis Investigative Site

Bristol, Tennessee, United States

Site Status

Novartis Investigative Site

Nashville, Tennessee, United States

Site Status

Novartis Investigative Site

San Antonio, Texas, United States

Site Status

Novartis Investigative Site

Burlington, Vermont, United States

Site Status

Novartis Investigative Site

Charlottesville, Virginia, United States

Site Status

Novartis Investigative Site

Seattle, Washington, United States

Site Status

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Site Status

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Site Status

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Site Status

Novartis Investigative Site

Capital Federal, Buenos Aires, Argentina

Site Status

Novartis Investigative Site

Villa Nueva, Mendoza Province, Argentina

Site Status

Novartis Investigative Site

Salta, Salta Province, Argentina

Site Status

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Site Status

Novartis Investigative Site

San Miguel de Tucumán, Tucumán Province, Argentina

Site Status

Novartis Investigative Site

Córdoba, , Argentina

Site Status

Novartis Investigative Site

Salta, , Argentina

Site Status

Novartis Investigative Site

Camperdown, New South Wales, Australia

Site Status

Novartis Investigative Site

Chatswood, New South Wales, Australia

Site Status

Novartis Investigative Site

Kogarah, New South Wales, Australia

Site Status

Novartis Investigative Site

Liverpool, New South Wales, Australia

Site Status

Novartis Investigative Site

North Gosford, New South Wales, Australia

Site Status

Novartis Investigative Site

Woodville, South Australia, Australia

Site Status

Novartis Investigative Site

Box Hill, Victoria, Australia

Site Status

Novartis Investigative Site

Fitzroy, Victoria, Australia

Site Status

Novartis Investigative Site

Heidelberg, Victoria, Australia

Site Status

Novartis Investigative Site

Parkville, Victoria, Australia

Site Status

Novartis Investigative Site

Innsbruck, Tyrol, Austria

Site Status

Novartis Investigative Site

Linz, , Austria

Site Status

Novartis Investigative Site

Salzburg, , Austria

Site Status

Novartis Investigative Site

Sankt Pölten, , Austria

Site Status

Novartis Investigative Site

Vienna, , Austria

Site Status

Novartis Investigative Site

Vienna, , Austria

Site Status

Novartis Investigative Site

Fraiture En Condroz, Belgium, Belgium

Site Status

Novartis Investigative Site

Aalst, , Belgium

Site Status

Novartis Investigative Site

Bruges, , Belgium

Site Status

Novartis Investigative Site

Brussels, , Belgium

Site Status

Novartis Investigative Site

Brussels, , Belgium

Site Status

Novartis Investigative Site

Brussels, , Belgium

Site Status

Novartis Investigative Site

Charleroi, , Belgium

Site Status

Novartis Investigative Site

Leuven, , Belgium

Site Status

Novartis Investigative Site

Melsbroek, , Belgium

Site Status

Novartis Investigative Site

Overpelt, , Belgium

Site Status

Novartis Investigative Site

Sijsele, , Belgium

Site Status

Novartis Investigative Site

Sint-Truiden, , Belgium

Site Status

Novartis Investigative Site

Wilrijk, , Belgium

Site Status

Novartis Investigative Site

Rio de Janeiro, Rio de Janeiro, Brazil

Site Status

Novartis Investigative Site

Rio de Janeiro, Rio de Janeiro, Brazil

Site Status

Novartis Investigative Site

Rio de Janiero, Rio de Janeiro, Brazil

Site Status

Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Novartis Investigative Site

Campinas, São Paulo, Brazil

Site Status

Novartis Investigative Site

Ribeirão Preto, São Paulo, Brazil

Site Status

Novartis Investigative Site

Edmonton, Alberta, Canada

Site Status

Novartis Investigative Site

Burnaby, British Columbia, Canada

Site Status

Novartis Investigative Site

Vancouver, British Columbia, Canada

Site Status

Novartis Investigative Site

Victoria, British Columbia, Canada

Site Status

Novartis Investigative Site

Halifax, Nova Scotia, Canada

Site Status

Novartis Investigative Site

Kingston, Ontario, Canada

Site Status

Novartis Investigative Site

London, Ontario, Canada

Site Status

Novartis Investigative Site

Nepean, Ontario, Canada

Site Status

Novartis Investigative Site

Ottawa, Ontario, Canada

Site Status

Novartis Investigative Site

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Greenfield Park, Quebec, Canada

Site Status

Novartis Investigative Site

Montreal, Quebec, Canada

Site Status

Novartis Investigative Site

Montreal, Quebec, Canada

Site Status

Novartis Investigative Site

Montreal, Quebec, Canada

Site Status

Novartis Investigative Site

Québec, Quebec, Canada

Site Status

Novartis Investigative Site

Sherbrooke, Quebec, Canada

Site Status

Novartis Investigative Site

Regina, Saskatchewan, Canada

Site Status

Novartis Investigative Site

Brno, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Olomouc, CZE, Czechia

Site Status

Novartis Investigative Site

Ostrava-Poruba, , Czechia

Site Status

Novartis Investigative Site

Pardubice, , Czechia

Site Status

Novartis Investigative Site

Plzen - Lochotin, , Czechia

Site Status

Novartis Investigative Site

Prague, , Czechia

Site Status

Novartis Investigative Site

Prague, , Czechia

Site Status

Novartis Investigative Site

Rychnov nad Kněžnou, , Czechia

Site Status

Novartis Investigative Site

Teplice, , Czechia

Site Status

Novartis Investigative Site

Aarhus, , Denmark

Site Status

Novartis Investigative Site

Copenhagen, , Denmark

Site Status

Novartis Investigative Site

Alexandria, , Egypt

Site Status

Novartis Investigative Site

Cairo, , Egypt

Site Status

Novartis Investigative Site

Cairo, , Egypt

Site Status

Novartis Investigative Site

Tallinn, , Estonia

Site Status

Novartis Investigative Site

Helsinki, , Finland

Site Status

Novartis Investigative Site

Seinäjoki, , Finland

Site Status

Novartis Investigative Site

Tampere, , Finland

Site Status

Novartis Investigative Site

Turku, , Finland

Site Status

Novartis Investigative Site

Nancy, Cedex, France

Site Status

Novartis Investigative Site

Bordeaux, , France

Site Status

Novartis Investigative Site

Bron, , France

Site Status

Novartis Investigative Site

Caen, , France

Site Status

Novartis Investigative Site

Clermont-Ferrand, , France

Site Status

Novartis Investigative Site

Dijon, , France

Site Status

Novartis Investigative Site

Lille, , France

Site Status

Novartis Investigative Site

Marseille, , France

Site Status

Novartis Investigative Site

Montpellier, , France

Site Status

Novartis Investigative Site

Nice, , France

Site Status

Novartis Investigative Site

Paris, , France

Site Status

Novartis Investigative Site

Poissy, , France

Site Status

Novartis Investigative Site

Rennes, , France

Site Status

Novartis Investigative Site

Saint-Herblain, , France

Site Status

Novartis Investigative Site

Strasbourg, , France

Site Status

Novartis Investigative Site

Toulouse, , France

Site Status

Novartis Investigative Site

Ostfildern, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Munich, Bavaria, Germany

Site Status

Novartis Investigative Site

Regensburg, Bavaria, Germany

Site Status

Novartis Investigative Site

Cologne, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Aachen, , Germany

Site Status

Novartis Investigative Site

Aalen, , Germany

Site Status

Novartis Investigative Site

Abensberg, , Germany

Site Status

Novartis Investigative Site

Achim, , Germany

Site Status

Novartis Investigative Site

Alzenau in Unterfranken, , Germany

Site Status

Novartis Investigative Site

Aschaffenburg, , Germany

Site Status

Novartis Investigative Site

Augsburg, , Germany

Site Status

Novartis Investigative Site

Bad Honnef, , Germany

Site Status

Novartis Investigative Site

Bad Krozingen, , Germany

Site Status

Novartis Investigative Site

Bad Mergentheim, , Germany

Site Status

Novartis Investigative Site

Bad Neustadt an der Saale, , Germany

Site Status

Novartis Investigative Site

Bamberg, , Germany

Site Status

Novartis Investigative Site

Bamberg, , Germany

Site Status

Novartis Investigative Site

Bayreuth, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Bielefeld, , Germany

Site Status

Novartis Investigative Site

Bielefeld, , Germany

Site Status

Novartis Investigative Site

Bielefeld, , Germany

Site Status

Novartis Investigative Site

Bochum, , Germany

Site Status

Novartis Investigative Site

Bochum, , Germany

Site Status

Novartis Investigative Site

Bochum, , Germany

Site Status

Novartis Investigative Site

Bogen, , Germany

Site Status

Novartis Investigative Site

Bonn, , Germany

Site Status

Novartis Investigative Site

Böblingen, , Germany

Site Status

Novartis Investigative Site

Buchholz, , Germany

Site Status

Novartis Investigative Site

Buchholz in der Nordheide, , Germany

Site Status

Novartis Investigative Site

Chemnitz, , Germany

Site Status

Novartis Investigative Site

Cologne, , Germany

Site Status

Novartis Investigative Site

Cologne, , Germany

Site Status

Novartis Investigative Site

Dillingen, , Germany

Site Status

Novartis Investigative Site

Dresden, , Germany

Site Status

Novartis Investigative Site

Düsseldorf, , Germany

Site Status

Novartis Investigative Site

Emden, , Germany

Site Status

Novartis Investigative Site

Emmendingen, , Germany

Site Status

Novartis Investigative Site

Erbach im Odenwald, , Germany

Site Status

Novartis Investigative Site

Erfurt, , Germany

Site Status

Novartis Investigative Site

Erlangen, , Germany

Site Status

Novartis Investigative Site

Essen, , Germany

Site Status

Novartis Investigative Site

Essen, , Germany

Site Status

Novartis Investigative Site

Frankfurt, , Germany

Site Status

Novartis Investigative Site

Freiburg im Breisgau, , Germany

Site Status

Novartis Investigative Site

Greifswald, , Germany

Site Status

Novartis Investigative Site

Grevenbroich, , Germany

Site Status

Novartis Investigative Site

Hamburg, , Germany

Site Status

Novartis Investigative Site

Hamburg, , Germany

Site Status

Novartis Investigative Site

Hamburg, , Germany

Site Status

Novartis Investigative Site

Hamburg, , Germany

Site Status

Novartis Investigative Site

Hanover, , Germany

Site Status

Novartis Investigative Site

Hanover, , Germany

Site Status

Novartis Investigative Site

Hanover, , Germany

Site Status

Novartis Investigative Site

Heidelberg, , Germany

Site Status

Novartis Investigative Site

Hennigsdorf, , Germany

Site Status

Novartis Investigative Site

Herborn, , Germany

Site Status

Novartis Investigative Site

Homburg, , Germany

Site Status

Novartis Investigative Site

Ibbenbueren, , Germany

Site Status

Novartis Investigative Site

Itzehoe, , Germany

Site Status

Novartis Investigative Site

Jena, , Germany

Site Status

Novartis Investigative Site

Kaltenkirchen, , Germany

Site Status

Novartis Investigative Site

Kassel, , Germany

Site Status

Novartis Investigative Site

Krefeld, , Germany

Site Status

Novartis Investigative Site

Landshut, , Germany

Site Status

Novartis Investigative Site

Lappersdorf, , Germany

Site Status

Novartis Investigative Site

Leipzig, , Germany

Site Status

Novartis Investigative Site

Leipzig, , Germany

Site Status

Novartis Investigative Site

Lohr a. Main, , Germany

Site Status

Novartis Investigative Site

Ludwigshafen, , Germany

Site Status

Novartis Investigative Site

Magdeburg, , Germany

Site Status

Novartis Investigative Site

Mainz, , Germany

Site Status

Novartis Investigative Site

Mannheim, , Germany

Site Status

Novartis Investigative Site

Marburg, , Germany

Site Status

Novartis Investigative Site

München, , Germany

Site Status

Novartis Investigative Site

München, , Germany

Site Status

Novartis Investigative Site

München, , Germany

Site Status

Novartis Investigative Site

München, , Germany

Site Status

Novartis Investigative Site

Münster, , Germany

Site Status

Novartis Investigative Site

Nagold, , Germany

Site Status

Novartis Investigative Site

Neu-Ulm, , Germany

Site Status

Novartis Investigative Site

Neuburg an der Donau, , Germany

Site Status

Novartis Investigative Site

Neuruppin, , Germany

Site Status

Novartis Investigative Site

Oldenburg, , Germany

Site Status

Novartis Investigative Site

Osnabrück, , Germany

Site Status

Novartis Investigative Site

Pforzheim, , Germany

Site Status

Novartis Investigative Site

Potsdam, , Germany

Site Status

Novartis Investigative Site

Prien am Chiemsee, , Germany

Site Status

Novartis Investigative Site

Rostock, , Germany

Site Status

Novartis Investigative Site

Rüdersdorf, , Germany

Site Status

Novartis Investigative Site

Rülzheim, , Germany

Site Status

Novartis Investigative Site

Schwarzenbruck, , Germany

Site Status

Novartis Investigative Site

Schwendi, , Germany

Site Status

Novartis Investigative Site

Siegen, , Germany

Site Status

Novartis Investigative Site

Sinsheim, , Germany

Site Status

Novartis Investigative Site

Stade, , Germany

Site Status

Novartis Investigative Site

Stuttgart, , Germany

Site Status

Novartis Investigative Site

Stuttgart, , Germany

Site Status

Novartis Investigative Site

Stuttgart, , Germany

Site Status

Novartis Investigative Site

Stuttgart, , Germany

Site Status

Novartis Investigative Site

Teupitz, , Germany

Site Status

Novartis Investigative Site

Trier, , Germany

Site Status

Novartis Investigative Site

Tübingen, , Germany

Site Status

Novartis Investigative Site

Ulm, , Germany

Site Status

Novartis Investigative Site

Ulm, , Germany

Site Status

Novartis Investigative Site

Unterhaching, , Germany

Site Status

Novartis Investigative Site

Wendlingen, , Germany

Site Status

Novartis Investigative Site

Wermsdorf, , Germany

Site Status

Novartis Investigative Site

Wiesbaden, , Germany

Site Status

Novartis Investigative Site

Wuppertal, , Germany

Site Status

Novartis Investigative Site

Würzburg, , Germany

Site Status

Novartis Investigative Site

Würzburg, , Germany

Site Status

Novartis Investigative Site

Alexandroupoli, Evros, Greece

Site Status

Novartis Investigative Site

Heraklion Crete, Greece, Greece

Site Status

Novartis Investigative Site

Athens, GR, Greece

Site Status

Novartis Investigative Site

Athens, GR, Greece

Site Status

Novartis Investigative Site

Thessaloniki, GR, Greece

Site Status

Novartis Investigative Site

Athens, , Greece

Site Status

Novartis Investigative Site

Athens, , Greece

Site Status

Novartis Investigative Site

Athens, , Greece

Site Status

Novartis Investigative Site

Athens, , Greece

Site Status

Novartis Investigative Site

Pátrai, , Greece

Site Status

Novartis Investigative Site

Thessaloniki, , Greece

Site Status

Novartis Investigative Site

Thessaloniki, , Greece

Site Status

Novartis Investigative Site

Guatemala City, , Guatemala

Site Status

Novartis Investigative Site

Guatemala City, , Guatemala

Site Status

Novartis Investigative Site

Budapest, HUN, Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Budapest, , Hungary

Site Status

Novartis Investigative Site

Debrecen, , Hungary

Site Status

Novartis Investigative Site

Győr, , Hungary

Site Status

Novartis Investigative Site

Miskolc, , Hungary

Site Status

Novartis Investigative Site

Pécs, , Hungary

Site Status

Novartis Investigative Site

Szeged, , Hungary

Site Status

Novartis Investigative Site

Székesfehérvár, , Hungary

Site Status

Novartis Investigative Site

Veszprém, , Hungary

Site Status

Novartis Investigative Site

Dublin, , Ireland

Site Status

Novartis Investigative Site

Dublin, , Ireland

Site Status

Novartis Investigative Site

Ashkelon, , Israel

Site Status

Novartis Investigative Site

Haifa, , Israel

Site Status

Novartis Investigative Site

Ramat Gan, , Israel

Site Status

Novartis Investigative Site

Sefad, , Israel

Site Status

Novartis Investigative Site

Asti, AT, Italy

Site Status

Novartis Investigative Site

Acquaviva delle Fonti, BA, Italy

Site Status

Novartis Investigative Site

Bergamo, BG, Italy

Site Status

Novartis Investigative Site

Bologna, BO, Italy

Site Status

Novartis Investigative Site

Montichiari, BS, Italy

Site Status

Novartis Investigative Site

Cagliari, CA, Italy

Site Status

Novartis Investigative Site

Chieti, CH, Italy

Site Status

Novartis Investigative Site

Catania, CT, Italy

Site Status

Novartis Investigative Site

Catania, CT, Italy

Site Status

Novartis Investigative Site

Great Yarmouth, , United Kingdom

Site Status

Novartis Investigative Site

Liverpool, , United Kingdom

Site Status

Novartis Investigative Site

London, , United Kingdom

Site Status

Novartis Investigative Site

London, , United Kingdom

Site Status

Novartis Investigative Site

London, , United Kingdom

Site Status

Novartis Investigative Site

Middlesbrough, , United Kingdom

Site Status

Novartis Investigative Site

Newcastle upon Tyne, , United Kingdom

Site Status

Novartis Investigative Site

Northampton, , United Kingdom

Site Status

Novartis Investigative Site

Nottingham, , United Kingdom

Site Status

Novartis Investigative Site

Poole, , United Kingdom

Site Status

Novartis Investigative Site

Swindon, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Brazil Canada Czechia Denmark Egypt Estonia Finland France Germany Greece Guatemala Hungary Ireland Israel Italy Jordan Malaysia Netherlands Norway Panama Peru Poland Portugal Romania Russia Slovakia South Africa South Korea Spain Sweden Switzerland Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Cohen JA, Tenenbaum N, Bhatt A, Zhang Y, Kappos L. Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord. 2019 Sep 25;12:1756286419878324. doi: 10.1177/1756286419878324. eCollection 2019.

Reference Type DERIVED
PMID: 31598139 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-020515-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CFTY720D2399

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.